Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an update.
Resmed Inc has announced a proposed sale of securities under Rule 144, involving the sale of 8,009 common shares by Michael J. Farrell, an officer and director of the company. The transaction, facilitated through Fidelity Brokerage Services LLC, is set to take place on September 8, 2025, with an aggregate market value of approximately $2,227,590.84. This sale follows previous transactions by Farrell within the past three months, reflecting a strategic decision that may impact the company’s stock liquidity and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
Resmed Inc operates in the healthcare industry, focusing on the development and manufacturing of products related to respiratory care, particularly for sleep apnea and other chronic respiratory conditions. The company is known for its innovative solutions in medical devices and cloud-connected software applications, serving a global market with a strong emphasis on improving patient outcomes and quality of life.
Average Trading Volume: 950,990
Technical Sentiment Signal: Buy
Current Market Cap: A$61.77B
Learn more about RMD stock on TipRanks’ Stock Analysis page.